ORIC® Pharmaceuticals Presents Potential Best-in-Class Data for Enozertinib in 1L NSCLC Patients with EGFR Atypical Mutations at ESMO Congress 2026 and Plans to Advance Enozertinib into a Global Phase 3 Trial

Enozertinib showed an 84% confirmed systemic overall response rate and a 70% confirmed intracranial response rate in a first-line EGFR atypical population, with multiple intracranial complete responses. The population had more than double the baseline CNS metastasis rate of competitor datasets; the results were described as potentially best-in-class.